JP2016537327A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537327A5
JP2016537327A5 JP2016524109A JP2016524109A JP2016537327A5 JP 2016537327 A5 JP2016537327 A5 JP 2016537327A5 JP 2016524109 A JP2016524109 A JP 2016524109A JP 2016524109 A JP2016524109 A JP 2016524109A JP 2016537327 A5 JP2016537327 A5 JP 2016537327A5
Authority
JP
Japan
Prior art keywords
treatment
pharmaceutical composition
prevention
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537327A (ja
Filing date
Publication date
Priority claimed from GB201318414A external-priority patent/GB201318414D0/en
Priority claimed from GB201319824A external-priority patent/GB201319824D0/en
Priority claimed from GB201409014A external-priority patent/GB201409014D0/en
Application filed filed Critical
Priority claimed from PCT/EP2014/072073 external-priority patent/WO2015055690A1/en
Publication of JP2016537327A publication Critical patent/JP2016537327A/ja
Publication of JP2016537327A5 publication Critical patent/JP2016537327A5/ja
Pending legal-status Critical Current

Links

JP2016524109A 2013-10-17 2014-10-15 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤 Pending JP2016537327A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1318414.8 2013-10-17
GB201318414A GB201318414D0 (en) 2013-10-17 2013-10-17 Novel use
GB1319824.7 2013-11-11
GB201319824A GB201319824D0 (en) 2013-11-11 2013-11-11 Novel use
GB201409014A GB201409014D0 (en) 2014-05-21 2014-05-21 Novel use
GB1409014.6 2014-05-21
PCT/EP2014/072073 WO2015055690A1 (en) 2013-10-17 2014-10-15 Pi3k inhibitor for treatment of respiratory disease

Publications (2)

Publication Number Publication Date
JP2016537327A JP2016537327A (ja) 2016-12-01
JP2016537327A5 true JP2016537327A5 (enExample) 2017-11-24

Family

ID=51830285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524109A Pending JP2016537327A (ja) 2013-10-17 2014-10-15 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤

Country Status (9)

Country Link
US (1) US20160256466A1 (enExample)
EP (1) EP3057587A1 (enExample)
JP (1) JP2016537327A (enExample)
KR (1) KR20160062179A (enExample)
CN (1) CN105658218A (enExample)
AU (2) AU2014336250A1 (enExample)
CA (1) CA2923995A1 (enExample)
RU (1) RU2016112268A (enExample)
WO (1) WO2015055690A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833970A4 (en) * 2018-08-10 2022-04-20 Ceramic Oxide Fabricators Pty Ltd OXYGEN PROBE FOR A FURNACE
CN109337976A (zh) * 2018-12-24 2019-02-15 中国医学科学院北京协和医院 用于检测pik3cd基因e1021k位点突变的探针和引物组合及试剂盒

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
BR9604976A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
CA2323771A1 (en) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
EP1175422A2 (en) 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
SI1305329T2 (sl) 2000-08-05 2015-07-31 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
BRPI0212455B8 (pt) 2001-09-14 2021-05-25 Glaxo Group Ltd composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
EP1467730A4 (en) 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
DE60318188T2 (de) 2002-03-26 2008-12-11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
WO2003091204A1 (en) 2002-04-25 2003-11-06 Glaxo Group Limited Phenethanolamine derivatives
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
US20060089375A1 (en) 2002-09-16 2006-04-27 Allen David G Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
RU2332400C2 (ru) 2002-10-28 2008-08-27 Глаксо Груп Лимитед Производные фенэтаноламина для лечения респираторных заболеваний
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
KR20080065318A (ko) 2003-10-14 2008-07-11 글락소 그룹 리미티드 무스카린성 아세틸콜린 수용체 길항제
CN102028994B (zh) 2003-11-03 2013-04-24 葛兰素集团有限公司 流体分配装置
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20070111995A1 (en) 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
RU2391338C2 (ru) 2004-10-19 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные хинолина
WO2006072599A2 (en) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en) 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
WO2010083163A1 (en) * 2009-01-13 2010-07-22 Philadelphia Health And Education Corporation The role of p110 delta signaling in morbidity and lung pathology induced by influenza virus infection
MY160454A (en) * 2009-04-30 2017-03-15 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
US8686331B2 (en) * 2010-08-08 2014-04-01 Kla-Tencor Corporation Dynamic wavefront control of a frequency converted laser system
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts

Similar Documents

Publication Publication Date Title
Kellogg 3rd et al. Cellular senescence in idiopathic pulmonary fibrosis
JP2016512511A5 (enExample)
JP2014532647A5 (enExample)
CY1123346T1 (el) Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα
NZ596071A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
JP2016536303A5 (enExample)
CN103635189A (zh) 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
JP2022513516A (ja) 炎症疾病の処置における使用の為のキノリン誘導体
JP2020510661A5 (enExample)
JP2016534124A5 (enExample)
JP2016522254A5 (enExample)
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
JP2016199578A5 (enExample)
JP2016537327A5 (enExample)
RU2019111873A (ru) Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм
JP2016507546A5 (enExample)
AU2021200051A1 (en) Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and corticosteroid
RU2016112268A (ru) Ингибитор PI3K для лечения респираторного заболевания
JP2016533367A5 (enExample)
RU2013107659A (ru) ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε
JP2019515003A5 (enExample)
CN111757737A (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
JP2015500295A5 (enExample)
JP2015510125A5 (enExample)
Marova et al. Hormonal characteristics of recurrent ACTH-secreting pituitary adenomas